<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemoprevention presents a major strategy for the medical management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Most drugs used for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER) pathway </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, blockade of BER pathway is an attractive option to inhibit the spread of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Using an in silico approach, we performed a structure-based screen by docking small-molecules onto DNA polymerase β (Pol-β) and identified a potent anti-Pol-β compound, NSC-124854 </plain></SENT>
<SENT sid="4" pm="."><plain>Our goal was to examine whether NSC-124854 could enhance the therapeutic efficacy of DNA-<z:chebi fb="0" ids="22333">alkylating agent</z:chebi>, Temozolomide (TMZ), by blocking BER </plain></SENT>
<SENT sid="5" pm="."><plain>First, we determined the specificity of NSC-124854 for Pol-β by examining in vitro activities of APE1, Fen1, DNA ligase I, and Pol-β-directed single nucleotide (SN)- and long-patch (LP)-BER </plain></SENT>
<SENT sid="6" pm="."><plain>Second, we investigated the effect of NSC-124854 on the efficacy of TMZ to inhibit the growth of mismatch repair (MMR)-deficient and MMR-proficient <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines using in vitro clonogenic assays </plain></SENT>
<SENT sid="7" pm="."><plain>Third, we explored the effect of NSC-124854 on TMZ-induced in vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition of MMR-deficient and MMR-proficient colonic xenografts implanted in female homozygous <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="8" pm="."><plain>Our data showed that NSC-124854 has high specificity to Pol-β and blocked Pol-β-directed SN- and LP-BER activities in in vitro reconstituted system </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, NSC-124854 effectively induced the sensitivity of TMZ to MMR-deficient and MMR-proficient <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells both in vitro cell culture and in vivo <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings suggest a potential novel strategy for the development of highly specific structure-based inhibitor for the prevention of <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colonic tumor</z:e> progression </plain></SENT>
</text></document>